NEW YORK, November 15, 2016 /PRNewswire/ --
This morning, Stock-Callers reviews the Dug Makers segment with focuson four equities: Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), United Therapeutics Corporation (NASDAQ: UTHR), MEI Pharma Inc. (NASDAQ: MEIP), and SciClone Pharmaceuticals Inc. (NASDAQ: SCLN). Today's coverage follows Monday's mixed trading session
On Monday, shares in Rancho Cucamonga, California headquartered Amphastar Pharmaceuticals Inc. ended the session 1.96% lower at $20.52 with a total volume of 525,426 shares traded. Amphastar Pharma's shares have surged 14.00% in the last one month, 11.89% in the previous three months, and 47.63% in the past one year. Shares of the Company, which focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products, are trading at a PE ratio of 45.50. The stock is trading 8.67% above its 50-day moving average and 32.13% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 61.82. Visit us today and download your complete report on AMPH for free at:
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished Monday's session 5.79% higher at $134.35 with a total volume of 962,094 shares traded. Over the last one month and the previous three months, United Therapeutics' shares have gained 14.94% and 7.29%, respectively. Shares of the Company, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, are trading above its 50-day and 200-day moving averages by 11.77% and 14.13%, respectively. United Therapeutics' stock traded at a PE ratio of 9.06 and has an RSI of 68.94.
On October 28th, 2016, research firm Ladenburg Thalmann upgraded the Company's stock rating from 'Neutral' to 'Buy'. The complimentary research report on UTHR can be accessed at:
On Monday, shares in San Diego, California-based MEI Pharma Inc. recorded a trading volume of 188,746 shares. The stock ended the day 2.41% lower at $1.62. The stock is trading above its 200-day moving average by 9.63%. Furthermore, shares of MEI Pharma, which focuses on the clinical development of drugs for the treatment of cancer, have an RSI of 53.72. Register for free on Stock-Callers.com and download the PDF research report on MEIP at:
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s stock advanced 5.08%, to close the day at $10.35. The stock recorded a trading volume of 1.66 million shares, which was above its three months average volume of 394,130 shares. SciClone Pharma's shares have advanced 3.40% in the previous one month and 12.99% in the past one year. Shares of the Company, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, are trading 4.12% above its 50-day moving average. Additionally, the stock traded at a PE ratio of 13.91 and has an RSI of 61.90. Get free access to your research report on SCLN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...View All